Literature DB >> 17611674

Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration.

Herwig M Strik1, Katharina Schmidt, Paul Lingor, Lars Tönges, Wilfried Kugler, Mirko Nitsche, Gabriel A Rabinovich, Mathias Bähr.   

Abstract

Galectins are evolutionarily conserved beta-galactoside-binding lectins which recognize specific glycoconjugates on the cell surface and the extracellular matrix. Accumulating evidence indicates that these proteins are involved in a variety of physiological and pathological processes including tumor growth and metastasis. Up-regulated expression of galectin-1 is a hallmark of a variety of malignant tumors. Here, we examined the expression of galectin-1 in glioma cell lines, the influence of ionizing irradiation and the intracellular and extracellular effects of this protein on tumor cell proliferation and migration. Galectin-1 was detected in both A172 and U118 glioma cells by immunoblot analysis. Ionizing irradiation induced a statistically significant up-regulation in glioma cell lines. RNA-interference-mediated silencing resulted in a significant suppression of the proliferation of the A172 cells, while the addition of recombinant galectin-1 had no effect. On the other hand, the migratory capacity of both cell lines was reduced after galectin-1 down-regulation, and up-regulated by the addition of exogenous galectin-1. Our results provide evidence of a role for galectin-1 in the regulation of glioma cell proliferation and migration. While an intracellular mechanism seemed to prevail in galectin-1-mediated regulation of tumor cell proliferation, the control of cell migration was exerted by both intracellular and extracellular mechanisms. In addition, this protein was up-regulated by ionizing radiation, indicating that the blockade of this protein should be performed before radiotherapy to avoid any undesired stimulating effects. Given the multifactorial role of galectin-1 in the regulation of tumor escape and metastasis, we conclude that targeting galectin-1 may have therapeutic benefits in the treatment of malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611674

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  21 in total

Review 1.  Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions.

Authors:  Alexander V Timoshenko
Journal:  Cell Mol Life Sci       Date:  2015-08-06       Impact factor: 9.261

2.  Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.

Authors:  Florence Lefranc; Véronique Mathieu; Robert Kiss
Journal:  World J Biol Chem       Date:  2011-09-26

3.  Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.

Authors:  Peiwen Kuo; Scott V Bratman; David B Shultz; Rie von Eyben; Cato Chan; Ziwei Wang; Carmen Say; Aparna Gupta; Bill W Loo; Amato J Giaccia; Albert C Koong; Maximilian Diehn; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2014-09-04       Impact factor: 12.531

4.  Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

Authors:  Tina Verschuere; Matthias Van Woensel; Steffen Fieuws; Florence Lefranc; Veronique Mathieu; Robert Kiss; Stefaan W Van Gool; Steven De Vleeschouwer
Journal:  J Neurooncol       Date:  2013-07-04       Impact factor: 4.130

5.  TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling.

Authors:  Vincent M Paulino; Zhongbo Yang; Jean Kloss; Matthew J Ennis; Brock A Armstrong; Joseph C Loftus; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2010-09-29       Impact factor: 5.852

6.  Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.

Authors:  Jun Wei; Jason Barr; Ling-Yuan Kong; Yongtao Wang; Adam Wu; Amit K Sharma; Joy Gumin; Verlene Henry; Howard Colman; Waldemar Priebe; Raymond Sawaya; Frederick F Lang; Amy B Heimberger
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

7.  Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

Authors:  An Coosemans; Judit Decoene; Thaïs Baert; Annouschka Laenen; Ahmad Kasran; Tina Verschuere; Sven Seys; Ignace Vergote
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

8.  Glioma-associated cancer-initiating cells induce immunosuppression.

Authors:  Jun Wei; Jason Barr; Ling-Yuan Kong; Yongtao Wang; Adam Wu; Amit K Sharma; Joy Gumin; Verlene Henry; Howard Colman; Raymond Sawaya; Frederick F Lang; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

Review 9.  Galectin-1 links tumor hypoxia and radiotherapy.

Authors:  Peiwen Kuo; Quynh-Thu Le
Journal:  Glycobiology       Date:  2014-06-27       Impact factor: 4.313

Review 10.  Galectins and gliomas.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Robert Kiss; Florence Lefranc
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.